Laura E. Niklason Sells 811,172 Shares of Humacyte, Inc. (NASDAQ:HUMA) Stock

Humacyte, Inc. (NASDAQ:HUMA) CEO Laura E. Niklason sold 811,172 shares of Humacyte stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $4.44, for a total value of $3,601,603.68. Following the transaction, the chief executive officer now directly owns 2,419,712 shares in the company, valued at approximately $10,743,521.28. This trade represents a 25.11 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Humacyte Stock Down 0.7 %

NASDAQ HUMA opened at $4.38 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. Humacyte, Inc. has a 52-week low of $2.43 and a 52-week high of $9.97. The firm has a 50-day moving average price of $5.36 and a 200 day moving average price of $6.18.

Hedge Funds Weigh In On Humacyte

A number of large investors have recently modified their holdings of HUMA. Barclays PLC boosted its stake in shares of Humacyte by 177.6% in the third quarter. Barclays PLC now owns 236,742 shares of the company’s stock valued at $1,288,000 after buying an additional 151,458 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Humacyte by 9.6% in the third quarter. Geode Capital Management LLC now owns 2,040,218 shares of the company’s stock valued at $11,101,000 after acquiring an additional 179,120 shares during the period. XTX Topco Ltd boosted its position in shares of Humacyte by 48.8% during the 3rd quarter. XTX Topco Ltd now owns 34,049 shares of the company’s stock worth $185,000 after purchasing an additional 11,172 shares in the last quarter. Insigneo Advisory Services LLC acquired a new position in shares of Humacyte during the 3rd quarter worth $109,000. Finally, Wellington Management Group LLP increased its holdings in shares of Humacyte by 30.9% in the 3rd quarter. Wellington Management Group LLP now owns 254,411 shares of the company’s stock valued at $1,384,000 after purchasing an additional 60,087 shares in the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on HUMA. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Humacyte in a report on Wednesday, November 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price objective on shares of Humacyte in a research note on Friday, September 20th. BTIG Research reiterated a “buy” rating and set a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. EF Hutton Acquisition Co. I upgraded Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Benchmark reaffirmed a “buy” rating and set a $15.00 price objective on shares of Humacyte in a research report on Thursday, October 10th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Humacyte has a consensus rating of “Buy” and a consensus price target of $11.00.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.